IARC	International Agency for Research on Cancer
NCI	National Cancer Institute
NMSCs	Nonmelanoma skin cancers
SM	Sulfur mustard
NM	Nitrogen mustard
HDI	Human Development Index
siRNA	Small interfering RNA
mABs-drug	monoclonal AntiBody
MtRth	Metabolic RadioTherapy
DSB	DNA double-strand break
IT	Isomeric Transition
ISOLDE	Isotope Separator On-Line Detector
API	Active Pharmaceutical Ingredient
PET	Positron emission tomography
MRI	Magnetic resonance imaging
LET	Linear energy transfer
MIBG	Meta-iodobenzylguanidine
ARPI	Active radiopharmaceutical ingredients
RLT	Radioligand therapy
NCRT	Neoadjuvant chemoradiotherapy
ACRT	Adjuvant chemoradiotherapy
NETs	Neuroendocrine tumors
SST	Somatostatin
PRRT	Peptide receptor radionuclide therapy
PSMA	Prostate-specific membrane antigen
GEP	Gastroenteropancreatic
RTSR	Radioligand therapy of somatostatin receptor
MtMn	Metastatic melanoma
MC1R	Melanocortin- subtype 1 receptor
GPCRs	G protein-coupled receptors
α-MSH	α-Melanocyte-stimulating hormone
FES	18F-fluoroestradiol
ER	Estrogen Receptor
PR	Progesterone Receptor
HR	Hormone Receptor
FDG	8F-fluorodeoxyglucose
FR-α,β	Folate receptor alpha,beta
MSC	Mesenchymal stem cells
NNI	The National Nanotechnology Initiative
NCTCs	Nanocytostatic Therapeutic Complexes
PK	Pharmacokinetics
BD	Biodistribution
NOTA	1,4,7-Triazacyclononane-1,4,7-Triacetic Acid
NODAG	Glutaric Acid Derivative of NOTA
DOTA	1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid
DODAGA	Derivative of DOTA
NCTCs	Nanocytostatics
AuNPs	Gold nanoparticles
AgNPs	Silver nanoparticles
TrAbl	Thermal ablation
SPIONs	SuperParamagnetic Iron Oxide Nanoparticles
MIH	Magnetic induction hyperthermia
ROS	Reactive oxygen species
DAC	Depletion of antioxidant capability